| Business Summary | | Adolor
Corporation
is
a
therapeutic-based
biopharmaceutical
company.
The
Company
discovers,
develops
and
plans
to
commercialize
proprietary
pharmaceutical
products
for
the
treatment
of
pain
and
the
side
effects
that
are
caused
by
pain
treatments.
The
Company
has
a
portfolio
of
small-molecule
product
candidates
that
are
in
various
stages
of
development,
ranging
from
preclinical
studies
to
Phase
I
through
Phase
II/III
clinical
trials.
The
Company's
lead
product
candidate,
ADL
8-2698,
is
designed
to
selectively
block
the
effects
of
narcotic
analgesics
on
the
gastrointestinal
(GI)
tract.
ADL
8-2698
is
a
peripherally
acting,
GI
tract-restricted
mu
opioid
receptor
antagonist
that
is
designed
to
block
the
adverse
side
effects
of
narcotic
analgesics
on
the
GI
tract
without
blocking
their
beneficial
analgesic
effects. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Adolor
Corporation
is
a
development-stage
pharmaceutical
company
engaged
in
the
development
of
peripheral
and
central
analgesics
based
on
opiate
receptors
and
opiate-like
receptors.
For
the
six
months
ended
6/30/01,
revenues
totaled
$562
thousand,
up
from
$18
thousand.
Net
loss
applicable
to
comm.
fell
26%
to
$16.9
million.
Results
reflect
a
$500
thousand
milestone
payment
from
an
affiliate
of
GlaxoSmithKline,
partially
offset
by
increased
salaries
and
personnel
related
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| John Farrar, P.h.D., 56 Pres,
CEO, Director | $386K | $200K | Peter Schied, 58 CFO,
VP, Sec. | 220K | 234K | Andrew Reddick, 48 COO,
Sr. VP of Commercial Operations | 372K | -- | David Jackson, M.D., 54 Sr.
VP, R&D | -- | -- | Deanne Garver, 42 VP,
Preclinical Devel. and Projects Management | 203K | 54K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|